Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCS-VI: Hypofractionated vs Conventional Radiotherapy + HDR Brachy Boost in High Risk Prostate Cancer
NCT02303327Phase 3Active, not recruiting
- Sponsor
- Jewish General Hospital
- Start
- Jan 2015
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Jewish General Hospital. Primary endpoint: Acute and delayed toxicity differences measured by CTCAE version 4 at 180 days. Started Jan 2015; status: active, not recruiting.
Beyond the preview
Go deeper on NCT02303327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303327.